Composition for normalization of infradian rhythm

Patent metadata

Field	Value
Publication number	US-9782377-B2
Application number	US-54615804-A
Country	US
Kind code	B2
Filing date	Mar 26, 2004
Priority date	Mar 27, 2003
Publication date	Oct 10, 2017
Grant date	Oct 10, 2017

Abstract

A composition having a normalizing action for infradian rhythm and/or a synchronization promoting action for circadian rhythm (biological clock) containing arachidonic acid and/or an arachidonic acid-containing compound.

First claim

The invention claimed is:

1. A method of treating a patient requiring a normalizing action for infradian rhythm and/or a synchronization promoting action for circadian rhythm (biological clock) comprising:
administering a composition containing an arachidonic acid-containing compound to a patient in need thereof in an arachidonic acid amount of 0.1 to 2 g per day,
wherein the arachidonic acid-containing compound is an alcohol ester of arachidonic acid or triglyceride or glycolipid comprising arachidonic acid as a part of or all of the constituting fatty acids.

2. The method according to claim 1 , wherein the triglyceride comprising arachidonic acid as all of or a part of the constituting fatty acids is a triglyceride where medium-chain fatty acids are bonded to 1,3-positions and arachidonic acid is bonded to 2-position.

3. The method according to claim 2 , wherein the medium-chain fatty acid is selected from fatty acids having 6 to 12 carbons.

4. The method according to claim 3 , wherein the medium-chain fatty acid is selected from fatty acids having 8 carbons.

5. A method of treating a patient requiring a normalizing action of infradian rhythm and/or a synchronization promoting action for circadian rhythm (biological clock) comprising:
administering a composition containing a triglyceride comprising arachidonic acid as all of or a part of a constituting fatty acids to a patient in need thereof.

6. The method according to claim 5 , wherein the ratio of arachidonic acid of the triglycerides containing a triglyceride comprising arachidonic acid as all of or a part of the constituting fatty acids is not less than 10% by weight to total fatty acids which constitute the triglyceride.

7. The method according to claim 5 , wherein the triglyceride comprising arachidonic acid as all of or a part of the constituting fatty acids is extracted from a microorganism belonging to genus Mortierella.

8. The method according to claim 5 , wherein the triglyceride comprising arachidonic acid as all of or a part of the constituting fatty acids is a triglyceride which does not contain eicosapentaenoic acid or, even if contained, its amount is not more than 1%.

9. A method of treating a patient requiring a normalizing action of infradian rhythm and/or a synchronization promoting action for circadian rhythm (biological clock) comprising:
administering a composition containing triglycerides to a patient in need thereof, wherein the triglycerides contain not less than 5 mol % of a triglyceride having a medium-chain fatty acids bonded to 1,3-positions and arachidonic acid bonded to 2-position, and wherein the composition is administered in an arachidonic acid amount of 0.1 to 2 g per day.

10. The method according to claim 9 , wherein the medium-chain fatty acid is selected from fatty acids having 6 to 12 carbons.

11. The method according to claim 10 , wherein the medium-chain fatty acid is selected from fatty acids having 8 carbons.

12. A method according to claim 1 , wherein said administering alleviates in said patient a biorhythm disorder caused by abnormality of infradian rhythm.

13. The method according to claim 12 , wherein the composition is administered in an amount effective to alleviate a biorhythm disorder, wherein the biorhythm disorder is a sleep disorder.

14. The method according to claim 12 , wherein the composition alleviates a biorhythm disorder caused by retardation of synchronization of circadian rhythm (biological clock).

15. The method according to claim 14 , wherein the biorhythm disorder is jet lag, headache, tinnitus, palpitation, nausea, gastralgia, diarrhea or lowering in ability of judgment and concentration.

16. The method according to claim 12 , wherein the biorhythm disorder is delayed sleep phase syndrome.

17. The method according to claim 1 , wherein the composition is a food composition or a pharmaceutical composition.

18. The method according to claim 17 , wherein the arachidonic acid-containing compound is an alcohol ester of arachidonic acid, or triglyceride or glycolipid containing arachidonic acid as a part of or all of the constituting fatty acid.

19. The method according to claim 18 , wherein the triglyceride comprising arachidonic acid as all of or a part of the constituting fatty acids is a triglyceride where a medium-chain fatty acids are bonded to 1,3-positions and arachidonic acid is bonded to 2-position.

20. The method according to claim 19 , wherein the medium-chain fatty acid is selected from fatty acids having 6 to 12 carbons.

21. The method according to claim 20 , wherein the medium-chain fatty acid is selected from fatty acids having 8 carbons.

22. The method according to claim 1 , wherein the composition contains not less than 0.001% by weight of a triglyceride in which a medium-chain fatty acid is bonded to 1,3-positions and arachidonic acid is bonded to 2-position.

23. The method according to claim 22 , wherein the medium-chain fatty acid is selected from fatty acids having 6 to 12 carbons.

24. The method according to claim 23 , wherein the medium-chain fatty acid is selected from fatty acids having 8 carbons.

25. The method according to claim 17 , wherein the food composition is a functional food, a nutritional supplement, a designated health food or a geriatric food.

26. A method of treating a patient requiring a normalizing action for infradian rhythm and/or a synchronization promoting action for circadian rhythm (biological clock) comprising:
administering a composition containing a single active ingredient to a patient in need thereof,
wherein the single active ingredient consists of an arachidonic acid-containing compound,
wherein the arachidonic acid-containing compound is an alcohol ester of arachidonic acid or triglyceride or glycolipid comprising arachidonic acid as a part of or all of the constituting fatty acids, and wherein the composition is administered in an arachidonic acid amount of 0.1 to 2 g per day.

Assignees

• Akimoto Kengo
• Ono Yoshiko
• Kawashima Hiroshi
• Nagai Katsuya
• Suntory Holdings Ltd

Inventors

• Akimoto Kengo
• Ono Yoshiko
• Kawashima Hiroshi
• Nagai Katsuya

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P25/20

  Hypnotics; Sedatives · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title